Fibroblast-stimulating lipopeptide-1 as a potential mucosal adjuvant enhances mucosal and systemic immune responses to enterovirus 71 vaccine
Journal
Vaccine
Journal Volume
36
Journal Issue
29
Pages
4331-4338
Date Issued
2018
Author(s)
Abstract
To prevent viral infection at the site of entry, mucosal vaccines are potent tools for inducing IgA secretion for defense. Because Toll-like receptor (TLR) ligands serve as strong adjuvants, two ligands that mimic the structure of mycoplasmal and bacterial lipopeptides represent interesting vaccine candidates. Pam3CSK4, a synthetic triacylated lipopeptide, interacts with TLR2/1. Because fibroblast-stimulating lipopeptide-1 (FSL-1), a synthetic diacylated lipopeptide, is recognized by TLR2/6, we targeted the potential immuno-inducibility of Pam3CSK4 and FSL-1 as adjuvants of an enterovirus 71 (EV71) mucosal vaccine. Na?ve BALB/c mice were used for intranasal immunization three times over a 3-week interval, with results showing that EV71-specific IgG and IgA in serum, nasal washes, bronchoalveolar lavage fluid, and feces from the EV71 + FSL-1 group were significantly higher than levels observed in mice treated with EV71 + Pam3CSK4, EV71 alone, or the control group treated with phosphate-buffered saline. Furthermore, we observed more EV71-specific IgG and IgA-producing cells in treatments using EV71 formulated with FSL-1. Additionally, T cell-proliferative responses and interferon-γ and interleukin-17 secretion were significantly increased when inactivated EV71 was formulated using FSL-1. Moreover, serum from immunized mice was capable of neutralizing the infectivity of EV71 (C2 genotype) and was able to cross-neutralize the B4 and B5 genotypes of EV71. Our data suggested that FSL-1 could be used as an efficient adjuvant for intranasal EV71-vaccine immunization. ? 2018
SDGs
Other Subjects
EV71 vaccine; fibroblast stimulating lipopeptide 1; gamma interferon; immunoglobulin A; immunoglobulin G; immunological adjuvant; interleukin 17; lipopeptide; Pam3CSK4; phosphate buffered saline; toll like receptor 1; toll like receptor 2; toll like receptor 6; unclassified drug; virus antibody; virus vaccine; diacylglycerol; FSL-1 lipoprotein, synthetic; gamma interferon; immunoglobulin A; immunoglobulin G; immunological adjuvant; interleukin 17; lipopeptide; oligopeptide; Pam(3)CSK(4) peptide; virus vaccine; animal cell; animal experiment; animal tissue; Article; Bagg albino mouse; bronchoalveolar lavage fluid; controlled study; cytokine response; Enterovirus A71; feces; genotype; immune response; immunoglobulin production; immunostimulation; lymphocyte proliferation; mouse; nasal lavage fluid; nonhuman; nose mucosa; priority journal; spleen cell; virus infectivity; virus neutralization; animal; blood; cell proliferation; chemistry; Enterovirus A; Enterovirus infection; female; immunization; immunology; intranasal drug administration; nose mucosa; secretion (process); T lymphocyte; Adjuvants, Immunologic; Administration, Intranasal; Animals; Antibodies, Viral; Bronchoalveolar Lavage Fluid; Cell Proliferation; Diglycerides; Enterovirus A, Human; Enterovirus Infections; Feces; Female; Immunization Schedule; Immunoglobulin A; Immunoglobulin G; Interferon-gamma; Interleukin-17; Lipopeptides; Mice, Inbred BALB C; Nasal Mucosa; Oligopeptides; T-Lymphocytes; Viral Vaccines
Publisher
Elsevier Ltd
Type
journal article